Memixa

Memantine Hydrochloride, the active ingredient in Memixa, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to reduce glutamate‑mediated neuronal excitotoxicity and support cognitive function.

GNH USA supplies Memixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring timely delivery and regulatory compliance.

Memixa, a NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive disorders.

Alzheimer’s disease (moderate to severe): improves cognition, functional abilities and overall clinical status. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression in some patients. Vascular dementia (off‑label): sometimes employed to provide modest symptomatic relief of cognitive deficits. Lewy body dementia (off‑label): can be considered to address fluctuating cognition and visual hallucinations.

Memixa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Fatigue

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic injury - Suicidal thoughts or behavior - Psychosis or severe agitation

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Renal impairment: assess renal function and consider dose adjustment. Hepatic disease: monitor liver enzymes regularly. History of seizures: use with caution and observe for seizure activity. Concurrent anticholinergic agents: may diminish therapeutic benefit. Cardiovascular disease: monitor blood pressure and heart rate. Store below 25°C: keep in the original pack, protect from moisture.

Memixa can interact with several medicines; careful review of a patient’s regimen is recommended.

Major Interactions (Avoid): - Strong CYP450 inhibitors (e.g., ketoconazole): increase memantine plasma concentrations. - NMDA agonists: may counteract therapeutic effect and raise neurotoxicity risk.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: potential reduction in cognitive benefit. - Diuretics (e.g., furosemide): may enhance hypotensive effects. - Antihypertensive agents: monitor blood pressure for additive lowering.